Aprea Therapeutics, Inc. (APRE) announced on Thursday that Nadeem Q. Mirza, who has been part of the company's senior team as a consultant since February 2023, will be taking on the role of Chief Medical Officer, effective May 1, 2024.
Mirza has over 30 years of clinical and developmental experience in solid tumors and hematologic malignancies. Before joining Aprea Therapeutics, Mirza served as Senior Vice President of Clinical Development at Salarius Pharmaceuticals.
Currently, APRE's stock is trading at $5.25, up 2.74% on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.